Citations

Clear

4207 citation(s) found for "Chen, Yu".

636 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc T cell engager in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
Uboha, Nataliya V. , Chaves, Jorge, Chen, Christopher T. , Powderly, John D. , Zhaohui, Jin, Alistar, Angela , Gabrail, Nashat , Agensky, Laura, Goel, Apollina, Margossian, Steven, Levisetti, Matteo, Quayle, Steve, Kim, Dae Won , Alese, Olatunji B. , Saenger, Yvonne M. , Zheng, Lei , Fu, Siqing , Gong, Jun , Zhaohui, Jin, Bekaii‐Saab, Tanios , Selfridge, Jennifer Eva

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A730-A730

10.1136/jitc-2024-sitc2024.0636 Get It

3D‐Printed Polymeric Biomaterials for Health Applications
Zhu, Yuxiang , Guo, Shenghan , Ravichandran, Dharneedar , Ramanathan, Arunachalam , Sacco, Alaina F., Patil, Dhanush , Thummalapalli, Sri Vaishnavi , Pulido, Tiffany V., Lancaster, Jessica N. , Yi, Johnny , Cornella, Jeffrey L. , Wang, Linbing , Zhao, Yiping , Chambers, Lindsay B. , Theobald, Taylor G. , Yang, Sui , Liang, Liang, Song, Kenan , Patil, Dhanush , Thummalapalli, Sri Vaishnavi , Lancaster, Jessica N , Yi, Johnny , Chen, Xiangfan , Mei, Xuan , Zhang, Yu Shrike , Wang, Linbing , Wang, Xianqiao , Zhao, Yiping , Hassan, Mohammad K , Yang, Sui , Song, Kenan , Ravichandran, Dharneedar , Zhu, Yuxiang , Ramanathan, Arunachalam , Sobczak, M. Taylor , Sacco, Alaina F., Lott, David G. , Chen, Xiangfan , Mei, Xuan , Zhang, Yu Shrike , Liang, Liang

Mayo Clinic

Advanced Healthcare Materials | November 5, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/adhm.202402571 | PMID 39498750 Get It

Abstract 3D printing, also known as additive manufacturing, holds immense potential for rapid prototyping and customized production of functional health‐related devices. With advancements in polymer chemistry and biomedical engineering, polymeric biomaterials have become integral to 3D‐printed biomedical applications. However, there still exists a bottleneck in the compatibility of polymeric biomaterials with different 3D printing methods, as well as intrinsic challenges such as limited printing resolution and rates. Therefore, this review aims to introduce the current state‐of‐the‐art in 3D‐printed functional polymeric health‐related devices. It begins with an overview of the landscape of 3D printing techniques, followed by an examination of commonly used polymeric biomaterials. Subsequently, examples of 3D‐printed biomedical devices are provided and classified into categories such as biosensors, bioactuators, soft robotics, energy storage systems, self‐powered devices, and data science in bioplotting. The emphasis is on exploring the current capabilities of 3D printing in manufacturing polymeric biomaterials into desired geometries that facilitate device functionality and studying the reasons for material choice. Finally, an outlook with challenges and possible improvements in the near future is presented, projecting the contribution of general 3D printing and polymeric biomaterials in the field of healthcare.
Non-canonical CDK6 activity promotes cilia disassembly by suppressing axoneme polyglutamylation
He, Kai , Sun, Xiaobo , Luc, San , Hao, Jielu , Zhang, Yingyi , Huang, Yan , Ji, Biyun , Ku, Pei-I , Subramanian, Radhika , Ling, Kun , Hu, Jinghua , Chen, Chuan , Luc, San , Robichaud, Jielu Hao , Zhang, Yingyi , Huang, Yan , Ji, Biyun , Ku, Pei-I , Subramanian, Radhika , Ling, Kun , Hu, Jinghua , He, Kai , Chen, Chuan

Mayo Clinic

Journal of Cell Biology | November 2, 2024 | Volume: 224 | Issue: 2 | Pages: No page available

10.1083/jcb.202405170 | PMID 39636239 Get It

Tubulin polyglutamylation is a posttranslational modification that occurs primarily along the axoneme of cilia. Defective axoneme polyglutamylation impairs cilia function and has been correlated with ciliopathies, including Joubert Syndrome (JBTS). However, the precise mechanisms regulating proper axoneme polyglutamylation remain vague. Here, we show that cyclin-dependent kinase 6 (CDK6), but not its paralog CDK4, localizes to the cilia base and suppresses axoneme polyglutamylation by phosphorylating RAB11 family interacting protein 5 (FIP5) at site S641, a critical regulator of cilia import of glutamylases. S641 phosphorylation disrupts the ciliary recruitment of FIP5 and its association with RAB11, thereby reducing the ciliary import of glutamylases. Encouragingly, the FDA-approved CDK4/6 inhibitor Abemaciclib can effectively restore cilia function in JBTS cells with defective glutamylation. In summary, our study elucidates the regulatory mechanisms governing axoneme polyglutamylation and suggests that developing CDK6-specific inhibitors could be a promising therapeutic strategy to enhance cilia function in ciliopathy patients.
Reforming Health Economics and Policy Curriculum to Form a Path for Changemaking in Medicine
Hiredesai, Annika N. , Chen, Xindi (Cece) , Chen, Xindi (Cece)

Mayo Clinic

Academic Medicine | November 1, 2024 | Volume: 100 | Issue: 2 | Pages: 121-121

10.1097/acm.0000000000005910 | PMID 39485122 Get It

Teflon Granuloma With Active Inflammation: A Cause of Recurrent Trigeminal Neuralgia After Microvascular Decompression
Herber, Steven C., Zimmerman, Richard S. , Yang, Ming , Martinez, Felipe , Herber, Steven, Chen, Alicia

Mayo Clinic

Clinical Nuclear Medicine | October 31, 2024 | Volume: 49 | Issue: 12 | Pages: 1105-1108

10.1097/rlu.0000000000005444 | PMID 39479994 Get It

Abstract Trigeminal neuralgia (TN) is characterized by excruciating facial pain usually caused by neurovascular compression of the trigeminal nerve roots. TN can be treated medically or invasively. Microvascular decompression is the procedure of choice and usually results in complete symptom relief. During surgical decompression, Teflon can be placed between the offending vessel and the nerve root entry zone. In some cases, chronic Teflon-related inflammation can cause recurrent TN, which might lead to additional surgical intervention. We present imaging and histopathological correlation of a patient presenting with intractable recurrent TN approximately 2 years after microvascular decompression with Teflon implant.
Survey of Post‐Prophylaxis Delayed‐Onset Cytomegalovirus Management Strategies Among Transplant Providers
Non, Lemuel , Tan, Chen Sabrina , İnce, Dilek , Razonable, Raymund R., Non, Lemuel R , Ince, Dilek , Razonable, Raymund R.

Mayo Clinic

Clinical Transplantation | October 30, 2024 | Volume: 38 | Issue: 11 | Pages: No page available

10.1111/ctr.70015 | PMID 39476330 Get It

ABSTRACTBackgroundPreventive strategies for cytomegalovirus (CMV) in the posttransplant period have changed the pattern of CMV infections, now more commonly manifesting as late‐onset occurrences known as post‐prophylaxis delayed‐onset CMV disease (PPDOC). We conducted a survey to investigate provider practices in managing PPDOC.MethodsA web‐based provider survey on the management of PPDOC was developed using Research Electronic Data Capture (REDCap). It was distributed to the online forums of the American Society of Transplantation communities of practice (COP) for Infectious Diseases (IDCOP), Kidney and Pancreas (KPCOP), Liver and Intestinal (LICOP), and Thoracic and Critical Care (TCCOP). The survey was posted twice within a span of a month.ResultsFifty‐six respondents, comprising 50 (89%) transplant physicians and 6 (11%) transplant pharmacists, from 46 distinct transplant centers, completed the survey. Universal antiviral prophylaxis (UAP) was the predominant preventive approach for both high‐risk (85%) and moderate‐risk (85%) transplant recipients. Out of 56, 51 respondents completed the questions regarding management of PPDOC. Regular surveillance with nucleic acid amplification tests (NAAT) (88%) was the most commonly used approach in high‐risk recipients, while symptom monitoring (73%) was the most common strategy in moderate‐risk recipients. Immunologic monitoring was used only by a few respondents who found it moderately useful in high‐risk recipients.ConclusionManagement of PPDOC was highly variable among providers and strategies differed based on patient risk profile. These findings could help shape future studies and guidelines to harmonize CMV management.
Cell migration simulator-based biomarkers for glioblastoma
Hou, Jay , McMahon, Mariah, Jubenville, Tyler , Chen, Clark C. , McMahon, Mariah , Odde, David J , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology Advances | October 29, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae184 | PMID 39605317 Get It

Abstract Background Glioblastoma is the most aggressive malignant brain tumor with poor survival due to its invasive nature driven by cell migration, with unclear linkage to transcriptomic information. The aim of this study was to develop a physics-based framework connecting to transcriptomics to predict patient-specific glioblastoma cell migration. Methods and Results We applied a physics-based motor-clutch model, a cell migration simulator (CMS), to parameterize the migration of glioblastoma cells and define physical biomarkers on a patient-by-patient basis. We reduced the 11-dimensional parameter space of the CMS into 3 principal physical parameters that govern cell migration: motor number—describing myosin II activity, clutch number—describing adhesion level, and F-actin polymerization rate. Experimentally, we found that glioblastoma patient-derived (xenograft) cell lines across mesenchymal (MES), proneural, and classical subtypes and 2 institutions (N = 13 patients) had optimal motility and traction force on stiffnesses around 9.3 kPa, with otherwise heterogeneous and uncorrelated motility, traction, and F-actin flow. By contrast, with the CMS parameterization, we found that glioblastoma cells consistently had balanced motor/clutch ratios to enable effective migration and that MES cells had higher actin polymerization rates resulting in higher motility. The CMS also predicted differential sensitivity to cytoskeletal drugs between patients. Finally, we identified 18 genes that correlated with the physical parameters, suggesting transcriptomic data alone could potentially predict the mechanics and speed of glioblastoma cell migration. Conclusions We describe a general physics-based framework for parameterizing individual glioblastoma patients and connecting to clinical transcriptomic data that can potentially be used to develop patient-specific anti-migratory therapeutic strategies.
FBF1 Deficiency Protects against Chronic Progression of Cisplatin-Induced AKI
Robichaud, Jielu Hao, Sun, Xiaobo , Hu, Jinghua , Hao, Jielu , Chen, Chuan , He, Kai , Dong, Zheng

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024hankv8re Get It

Artificial Intelligence/Machine Learning Externally Validated Models for AKI Risk-Classification: A Systematic Review and Meta-Analysis
Braun, Chloe G. , Chen, Jin, Kane‐Gill, Sandra L. , Ninan, Jacob, Neyra, Javier A. , Kane-Gill, Sandra L , Cama-Olivares, Augusto , Takeuchi, Tomonori , Kaiser, Kathryn A. , Ghazi, Lama , Chen, Jin, Forni, Lui G. , Ostermann, Marlies , Shickel, Benjamin

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024mp7992ze Get It